<DOC>
	<DOC>NCT01078662</DOC>
	<brief_summary>To assess the efficacy of oral olaparib in patients with advanced cancer who have a confirmed genetic BRCA1 and/or BRCA2 mutation, by assessment of tumour response</brief_summary>
	<brief_title>Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats</brief_title>
	<detailed_description />
	<mesh_term>Olaparib</mesh_term>
	<criteria>Confirmed documented deleterious or suspected deleterious BRCA mutation. (The presence of a lossoffunction germline mutation in the BRCA1 and/or BRCA2 gene must be confirmed prior to consent according to local practice). Confirmed malignant solid tumours for which no standard treatment exists At least one lesion (measurable and/or non measurable) at baseline that can be accurately assessed by CT/MRI and is suitable for repeated assessment at follow up visits Any previous treatment with a PARP inhibitor, including olaparib Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication Patients receiving any systematic chemotherapy, radiotherapy (except for palliative reasons) within 2 weeks from the last dose prior to study treatment (or a longer period depending on the defined characteristics of the agents used)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>olaparib</keyword>
	<keyword>PARP inhibitors</keyword>
	<keyword>genetic BRCA1 mutation</keyword>
	<keyword>BRCA2 mutation</keyword>
	<keyword>solid tumour refractory</keyword>
</DOC>